ES533668A0
(es)
*
|
1983-06-24 |
1985-10-01 |
Yamanouchi Pharma Co Ltd |
Un compuesto fenoxi
|
CN1003445B
(zh)
*
|
1984-10-03 |
1989-03-01 |
武田药品工业株式会社 |
噻唑烷二酮衍生物,其制备方法和用途
|
US4812570A
(en)
*
|
1986-07-24 |
1989-03-14 |
Takeda Chemical Industries, Ltd. |
Method for producing thiazolidinedione derivatives
|
FI91869C
(fi)
*
|
1987-03-18 |
1994-08-25 |
Tanabe Seiyaku Co |
Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
|
HU203330B
(en)
*
|
1987-06-10 |
1991-07-29 |
Pfizer |
Process for producing oxazolidin-2-one derivatives and hypoglychemic pharmaceutical compositions containing them
|
EP0295828A1
(de)
*
|
1987-06-13 |
1988-12-21 |
Beecham Group Plc |
Chemische Verbindungen
|
GB8713861D0
(en)
*
|
1987-06-13 |
1987-07-15 |
Beecham Group Plc |
Compounds
|
US4791125A
(en)
*
|
1987-12-02 |
1988-12-13 |
Pfizer Inc. |
Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
|
US4798835A
(en)
*
|
1987-12-02 |
1989-01-17 |
Pfizer Inc. |
dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
|
GB8820389D0
(en)
*
|
1988-08-26 |
1988-09-28 |
Beecham Group Plc |
Novel compounds
|
GB8919417D0
(en)
|
1989-08-25 |
1989-10-11 |
Beecham Group Plc |
Novel compounds
|
US4997948A
(en)
*
|
1989-10-27 |
1991-03-05 |
American Home Products |
5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
|
US5356913A
(en)
*
|
1990-02-09 |
1994-10-18 |
The Upjohn Company |
Use of insulin sensitizing agents to treat hypertension
|
DK0514452T4
(da)
†
|
1990-02-09 |
2000-09-18 |
Upjohn Co |
Anvendelse af insulin-sensibiliserende midler til behandling af hypertension
|
EP0839812A1
(de)
*
|
1990-04-27 |
1998-05-06 |
Sankyo Company Limited |
Herstellung von Benzylthiazolidinederivaten
|
GB9023584D0
(en)
*
|
1990-10-30 |
1990-12-12 |
Beecham Group Plc |
Novel compounds
|
US5158966A
(en)
*
|
1991-02-22 |
1992-10-27 |
The University Of Colorado Foundation, Inc. |
Method of treating type i diabetes
|
US5183823A
(en)
*
|
1991-04-11 |
1993-02-02 |
Takeda Chemical Industries, Ltd. |
Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
|
KR100249988B1
(ko)
*
|
1991-04-11 |
2000-04-01 |
로렌스 티. 마이젠헬더 |
티아졸리딘디온 유도체, 그의 제조방법 및 용도
|
US5441971A
(en)
*
|
1991-04-11 |
1995-08-15 |
The Upjohn Company |
Thiazolidinedione derivatives, production and use thereof
|
FR2680512B1
(fr)
*
|
1991-08-20 |
1995-01-20 |
Adir |
Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
|
GB9124513D0
(en)
*
|
1991-11-19 |
1992-01-08 |
Smithkline Beecham Plc |
Novel process
|
US5741803A
(en)
*
|
1992-09-05 |
1998-04-21 |
Smithkline Beecham Plc |
Substituted thiazolidinedionle derivatives
|
GB9218830D0
(en)
*
|
1992-09-05 |
1992-10-21 |
Smithkline Beecham Plc |
Novel compounds
|
EP0915090A1
(de)
*
|
1992-09-10 |
1999-05-12 |
Eli Lilly And Company |
Thiazolidinone Derivate als hypoglykämisches Mittel und für die Behandlung der Alzheimer Krankheit
|
JP2845743B2
(ja)
*
|
1992-12-28 |
1999-01-13 |
三菱化学株式会社 |
新規なナフタレン誘導体
|
US5594016A
(en)
*
|
1992-12-28 |
1997-01-14 |
Mitsubishi Chemical Corporation |
Naphthalene derivatives
|
USRE39384E1
(en)
|
1993-09-01 |
2006-11-07 |
Smithkline Beecham P.L.C. |
Substituted thiazolidinedione derivatives
|
ATE376829T1
(de)
*
|
1993-09-15 |
2007-11-15 |
Daiichi Sankyo Co Ltd |
Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm)
|
US5874454A
(en)
*
|
1993-09-15 |
1999-02-23 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US6046222A
(en)
*
|
1993-09-15 |
2000-04-04 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US5478852C1
(en)
*
|
1993-09-15 |
2001-03-13 |
Sankyo Co |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
|
ATE183743T1
(de)
*
|
1994-03-08 |
1999-09-15 |
American Home Prod |
Thiazolidine-dion-derivate als antihyperglykemische mittel
|
US6251928B1
(en)
|
1994-03-16 |
2001-06-26 |
Eli Lilly And Company |
Treatment of alzheimer's disease employing inhibitors of cathepsin D
|
KR100356551B1
(ko)
*
|
1994-10-20 |
2002-12-18 |
닛뽕 케미파 가부시키가이샤 |
퀴놀린유도체
|
US5708012A
(en)
*
|
1995-04-28 |
1998-01-13 |
Sankyo Company, Limited |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
|
AU5121796A
(en)
*
|
1995-05-08 |
1996-11-29 |
Nippon Chemiphar Co. Ltd. |
2,4-thiazolidinedione or oxazolidinedione derivatives and hy poglycemic agent
|
TW438587B
(en)
|
1995-06-20 |
2001-06-07 |
Takeda Chemical Industries Ltd |
A pharmaceutical composition for prophylaxis and treatment of diabetes
|
NO318765B1
(no)
*
|
1995-07-03 |
2005-05-02 |
Sankyo Co |
Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
|
EP0783888A1
(de)
*
|
1995-12-26 |
1997-07-16 |
Sankyo Company Limited |
Verwendung von Troglitazone und verwandten Thiazolidinedionen zur Herstellung eines Medikaments für die Behandlung und Vorbeugung der Osteoporose
|
NZ314406A
(en)
*
|
1996-03-18 |
2000-12-22 |
Sankyo Co |
Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
|
JP2000511883A
(ja)
*
|
1996-04-19 |
2000-09-12 |
ノボ ノルディスク アクティーゼルスカブ |
ホスホチロシン認識ユニットを有する分子のモジュレーター
|
US5958957A
(en)
*
|
1996-04-19 |
1999-09-28 |
Novo Nordisk A/S |
Modulators of molecules with phosphotyrosine recognition units
|
CA2257284C
(en)
*
|
1996-05-31 |
2005-10-04 |
Sankyo Company Limited |
Remedy for autoimmune diseases
|
US5952509A
(en)
*
|
1996-06-27 |
1999-09-14 |
Takeda Chemical Industries, Ltd. |
Production of benzaldehyde compounds
|
ATE399545T1
(de)
*
|
1996-11-08 |
2008-07-15 |
Nippon Chemiphar Co |
Mittel zur verringerung der eigeweidefette
|
DE69838789T2
(de)
*
|
1997-03-12 |
2008-10-30 |
Suzanne Cambridge de la Monte |
Verfahren zur behandlung oder prävention der alzheimerischen krankheit
|
US5908859A
(en)
*
|
1997-08-11 |
1999-06-01 |
Eli Lilly And Company |
Benzothiophenes for inhibiting hyperlipidemia
|
HUP9902721A2
(hu)
|
1997-11-25 |
1999-12-28 |
The Procter & Gamble Co. |
Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
|
AU1507799A
(en)
*
|
1997-12-16 |
1999-07-05 |
Sankyo Company Limited |
Leukemia remedy
|
GB9726568D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US20040058873A1
(en)
*
|
1998-03-12 |
2004-03-25 |
Esmond Robert W. |
Method for treating or preventing Alzheimer's disease
|
WO2000030628A2
(en)
*
|
1998-11-20 |
2000-06-02 |
Genentech, Inc. |
Method of inhibiting angiogenesis
|
US6191154B1
(en)
|
1998-11-27 |
2001-02-20 |
Case Western Reserve University |
Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
|
TWI249401B
(en)
*
|
1999-04-14 |
2006-02-21 |
Takeda Chemical Industries Ltd |
Agent for improving ketosis
|
DE60035271D1
(en)
|
1999-04-28 |
2007-08-02 |
Inst Med Molecular Design Inc |
Pyrimidincarbonsäurederivate
|
JP2001072592A
(ja)
|
1999-07-01 |
2001-03-21 |
Kyowa Hakko Kogyo Co Ltd |
テロメラーゼ阻害剤
|
JP2003507473A
(ja)
*
|
1999-07-01 |
2003-02-25 |
ジェロン コーポレイション |
テロメラーゼインヒビターおよびその使用の方法
|
US7390824B1
(en)
*
|
1999-09-07 |
2008-06-24 |
Bristol-Myers Squibb Company |
Method for treating diabetes employing an aP2 inhibitor and combination
|
AR028299A1
(es)
|
1999-09-17 |
2003-05-07 |
Novartis Ag |
Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
US6878749B2
(en)
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
ES2156574B1
(es)
|
1999-11-18 |
2002-02-01 |
Vita Invest Sa |
Nuevos derivados de tiazolidindiona como agentes antidiabeticos
|
AU782631C
(en)
|
1999-12-03 |
2006-08-17 |
Kyoto Pharmaceutical Industries, Ltd. |
Novel heterocyclic compounds and salts thereof and medicinal use of the same
|
PT1248604E
(pt)
|
2000-01-21 |
2007-01-31 |
Novartis Ag |
Associações compreendendo inibidor de dipeptidilpeptidase-iv
|
US6784199B2
(en)
*
|
2000-09-21 |
2004-08-31 |
Aryx Therapeutics |
Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals
|
US6680387B2
(en)
*
|
2000-04-24 |
2004-01-20 |
Aryx Therapeutics |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6958355B2
(en)
*
|
2000-04-24 |
2005-10-25 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
EA004244B1
(ru)
*
|
2000-04-25 |
2004-02-26 |
Киорин Фармасьютикал Ко., Лтд. |
Новый стабильный кристалл производного тиазолидиндиона и способ его получения
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
US6452014B1
(en)
|
2000-12-22 |
2002-09-17 |
Geron Corporation |
Telomerase inhibitors and methods of their use
|
ATE341343T1
(de)
*
|
2000-12-26 |
2006-10-15 |
Sankyo Co |
Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
|
US20020183305A1
(en)
*
|
2001-01-26 |
2002-12-05 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
PL205343B1
(pl)
*
|
2001-01-26 |
2010-04-30 |
Schering Corp |
Zastosowanie inhibitora wchłaniania sterolu
|
PT1353694E
(pt)
*
|
2001-01-26 |
2008-03-12 |
Schering Corp |
Combinações de ezetimiba com aspirina para o tratamento de doenças vasculares
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
SI1353696T1
(sl)
*
|
2001-01-26 |
2007-04-30 |
Schering Corp |
Kombinacije aktivatorja(-ev) peroksisomskega proliferatorja aktivirajocega receptorja (PPAR) in inhibitorja(-ev) absorpcije sterola in oblike zdravljenja za vaskularne indikacije
|
CA2434033A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
AR032643A1
(es)
*
|
2001-01-26 |
2003-11-19 |
Schering Corp |
Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares
|
BRPI0207767B8
(pt)
*
|
2001-02-24 |
2021-05-25 |
Boehringer Ingelheim Pharma |
derivados de xantina, seu uso, composições farmacêuticas, seus processos de preparação, e sais fisiologicamente aceitáveis
|
KR200249057Y1
(ko)
*
|
2001-03-22 |
2001-10-19 |
김진환 |
뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
|
WO2002080936A1
(en)
*
|
2001-04-04 |
2002-10-17 |
Ortho Mcneil Pharmaceutical, Inc. |
Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
|
US20060047000A1
(en)
*
|
2001-04-24 |
2006-03-02 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US20040077689A1
(en)
*
|
2001-04-25 |
2004-04-22 |
Yasuo Sugiyama |
Abc expression promoters
|
EE200300519A
(et)
|
2001-04-26 |
2004-02-16 |
L�civa, a.s. |
Meetod pioglitasooni kui suhkurtõvevastase aine saamiseks
|
IL159085A0
(en)
*
|
2001-05-29 |
2004-05-12 |
Kyoto Pharma Ind |
Heterocyclic derivatives and pharmaceutical compositions containing the same
|
CN1522253A
(zh)
*
|
2001-05-29 |
2004-08-18 |
����ҩƷ��ҵ��ʽ���� |
新颖的杂环衍生物及其医疗用途
|
EP1413315A4
(de)
*
|
2001-08-03 |
2006-08-16 |
Takeda Pharmaceutical |
Medikamente mit verzögerter freisetzung
|
PT1427409E
(pt)
*
|
2001-09-21 |
2008-11-27 |
Schering Corp |
Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
DK1429756T3
(da)
*
|
2001-09-21 |
2007-03-19 |
Schering Corp |
Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US7135485B2
(en)
*
|
2001-09-28 |
2006-11-14 |
Teva Pharmaceutical Industries Ltd. |
Pioglitazone hydrochloride
|
US20050101638A1
(en)
*
|
2002-11-08 |
2005-05-12 |
Webb Randy L. |
Combination of organic compounds
|
US20050187258A1
(en)
*
|
2001-12-20 |
2005-08-25 |
Ben-Zion Dolitzky |
Hydrogenation of precursors to thiazolidinedione antihyperglycemics
|
CA2470075A1
(en)
*
|
2001-12-20 |
2003-07-03 |
Teva Pharmaceutical Industries Ltd. |
Hydrogenation of precursors to thiazolidinedione antihyperglycemics
|
ITRM20020016A1
(it)
*
|
2002-01-15 |
2003-07-15 |
Sigma Tau Ind Farmaceuti |
Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
|
JPWO2003062427A1
(ja)
*
|
2002-01-23 |
2005-05-26 |
山之内製薬株式会社 |
インスリン抵抗性改善薬のスクリーニング法
|
US7015345B2
(en)
*
|
2002-02-21 |
2006-03-21 |
Asahi Kasei Pharma Corporation |
Propionic acid derivatives
|
KR100450700B1
(ko)
*
|
2002-03-22 |
2004-10-01 |
주식회사종근당 |
티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
|
US20050119314A1
(en)
*
|
2002-04-05 |
2005-06-02 |
Sankyo Company, Limited |
Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
|
AU2002356419A1
(en)
|
2002-06-17 |
2003-12-31 |
Themis Laboratories Private Limited |
Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
|
US8993773B2
(en)
|
2002-07-16 |
2015-03-31 |
Cadila Healthcare Limited |
Process to prepare pioglitazone via several novel intermediates
|
AU2003272072A1
(en)
|
2002-07-16 |
2004-02-02 |
Cadila Healthcare Limited |
A process to prepare pioglitazone via several intermediates.
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
AU2003260813A1
(en)
*
|
2002-09-12 |
2004-04-30 |
Themis Laboratories Private Limited |
Improved process for preparation of thiazolidinedione derivatives
|
US7785627B2
(en)
*
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7959946B2
(en)
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US9060941B2
(en)
*
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
WO2004026241A2
(en)
|
2002-09-20 |
2004-04-01 |
Andrx Labs Llc |
Multistage formulation containing a biguanide and thiazolidindione derivatives
|
US8084058B2
(en)
|
2002-09-20 |
2011-12-27 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
CA2504916A1
(en)
*
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
ES2318274T3
(es)
|
2003-03-07 |
2009-05-01 |
Schering Corporation |
Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
|
US7192944B2
(en)
|
2003-03-07 |
2007-03-20 |
Schering Corp. |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
EP1601668B1
(de)
|
2003-03-07 |
2008-08-27 |
Schering Corporation |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
CN1894234A
(zh)
|
2003-03-25 |
2007-01-10 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
WO2004108721A1
(en)
*
|
2003-04-01 |
2004-12-16 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl] methyl]-2,4-thiazolidinedione
|
ES2219180B1
(es)
*
|
2003-05-09 |
2006-03-01 |
Medichem, S.A. |
Compuesto intermedio util para la preparacion de pioglitazona.
|
US7230016B2
(en)
*
|
2003-05-13 |
2007-06-12 |
Synthon Ip Inc. |
Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
|
US20050059708A1
(en)
*
|
2003-05-13 |
2005-03-17 |
Karel Pospisilik |
Processes for making thiazolidinedione derivatives and compounds thereof
|
SI1622899T1
(sl)
*
|
2003-05-13 |
2007-10-31 |
Synthon Bv |
Pioglitazonsulfat, farmacevtski sestavki in njihova uporaba
|
US20050004179A1
(en)
*
|
2003-05-22 |
2005-01-06 |
Pedersen Ward A. |
Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
|
JPWO2004106542A1
(ja)
*
|
2003-05-29 |
2006-07-20 |
三共株式会社 |
インスリン抵抗性改善剤及びそのスクリーニング方法
|
SG141430A1
(en)
|
2003-05-30 |
2008-04-28 |
Ranbaxy Lab Ltd |
Substituted pyrrole derivatives and their use as hmg-co inhibitors
|
KR20060041309A
(ko)
|
2003-08-13 |
2006-05-11 |
다케다 야쿠힌 고교 가부시키가이샤 |
4-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
|
US20070078170A1
(en)
*
|
2003-08-28 |
2007-04-05 |
Khanduri Chandra H |
Process for the preparation of pioglitazone
|
WO2005021543A1
(en)
*
|
2003-09-03 |
2005-03-10 |
Biocon Limited |
Phosphoric acid salt of 5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione
|
JP2007505121A
(ja)
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
WO2005027967A1
(ja)
*
|
2003-09-17 |
2005-03-31 |
Kaname Kawasugi |
医薬組成物
|
US20050096307A1
(en)
*
|
2003-11-05 |
2005-05-05 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
WO2005080387A2
(en)
|
2004-02-20 |
2005-09-01 |
Synthon B.V. |
Processes for making pioglitazone and compounds of the processes
|
AU2004318013B8
(en)
*
|
2004-03-15 |
2011-10-06 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CA2560928A1
(en)
*
|
2004-03-29 |
2005-10-06 |
Sankyo Company Limited |
Therapeutic agent for diabetes containing insulin resistance improving agent
|
US7161756B2
(en)
*
|
2004-05-10 |
2007-01-09 |
Tandberg Data Storage Asa |
Method and system for communication between a tape drive and an external device
|
US20060025478A1
(en)
*
|
2004-07-27 |
2006-02-02 |
Keisuke Inoue |
Medicine for prevention or treatment of diabetes
|
TW200608967A
(en)
*
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
US20070259927A1
(en)
*
|
2004-08-26 |
2007-11-08 |
Takeda Pharmaceutical Company Limited |
Remedy for Diabetes
|
WO2006035459A1
(en)
*
|
2004-09-28 |
2006-04-06 |
Morepen Laboratories Limited |
An improved process for the production of derivatives of thiozolidinediones and their precursors
|
US20060089387A1
(en)
*
|
2004-10-26 |
2006-04-27 |
Le Huang |
Stabilized pharmaceutical composition comprising antidiabetic agent
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
EP1828192B1
(de)
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidylpeptidasehemmer
|
BRPI0609371A2
(pt)
*
|
2005-03-08 |
2010-03-30 |
Nycomed Gmbh |
usos de roflumilast na produção de composições farmacêuticas para o tratamento de diabetes mellitus
|
US20070269486A1
(en)
*
|
2005-03-14 |
2007-11-22 |
Conor Medsystems, Llc. |
Methods and Devices for Reducing Tissue Damage After Ischemic Injury
|
KR20080025662A
(ko)
*
|
2005-03-18 |
2008-03-21 |
오키드 케미칼즈 앤드 파마수티컬즈 리미티드 |
신규 티로신 유도체
|
WO2006117654A1
(en)
*
|
2005-05-03 |
2006-11-09 |
Ranbaxy Laboratories Limited |
Processes for the preparation of pioglitazone or salts thereof
|
TW200740460A
(en)
*
|
2005-07-12 |
2007-11-01 |
Sankyo Co |
Pharmaceutical composition containing PPAR γ agonist
|
WO2007029062A2
(en)
*
|
2005-07-29 |
2007-03-15 |
Orchid Research Laboratories Limited |
Novel pyridine derivatives
|
DE102005035891A1
(de)
*
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
CA2622472C
(en)
*
|
2005-09-14 |
2013-11-19 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors for treating diabetes
|
US8222411B2
(en)
|
2005-09-16 |
2012-07-17 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
BRPI0618379A2
(pt)
|
2005-11-08 |
2011-08-30 |
Ranbaxy Lab Ltd |
processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
|
TW200730173A
(en)
*
|
2005-12-16 |
2007-08-16 |
Sankyo Co |
Pharmaceutical composition enhancing production of adiponectin
|
NZ571871A
(en)
|
2006-03-16 |
2011-07-29 |
Metabolic Solutions Dev Co |
Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
|
EP2001469B1
(de)
*
|
2006-03-16 |
2012-05-23 |
Metabolic Solutions Development Company LLC |
Thiazolidindion-analoga
|
JP2009530293A
(ja)
*
|
2006-03-16 |
2009-08-27 |
メタボリック ソリューションズ ディベロップメント カンパニー |
チアゾリジンジオン類似体およびグルココルチコイドアゴニストの併用療法
|
EP1852108A1
(de)
*
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Zusammensetzungen von DPP-IV-Inhibitoren
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
BRPI0711558A2
(pt)
|
2006-05-04 |
2011-11-08 |
Boeringer Ingelheim Internat Gmbh |
polimorfos
|
CA2787343C
(en)
|
2006-06-26 |
2016-08-02 |
Amgen Inc. |
Compositions comprising modified lcat and uses thereof
|
KR100791399B1
(ko)
|
2006-09-06 |
2008-01-07 |
동우신테크 주식회사 |
염산 피오글리타존의 제조방법
|
MEP8509A
(en)
|
2006-09-07 |
2011-12-20 |
|
Combination treatment for diabetes mellitus
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
US20080182880A1
(en)
*
|
2006-09-28 |
2008-07-31 |
Mailatur Sivaraman Mohan |
Pioglitazone composition
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
EP2125841A1
(de)
*
|
2006-12-13 |
2009-12-02 |
Gilead Sciences, Inc. |
Monophosphate als gemeinsame prodrugs für entzündungshemmende signalübertragungsmodulatoren und beta-agonisten für die behandlung von lungenentzündung und bronchokonstriktion
|
WO2008075380A2
(en)
*
|
2006-12-21 |
2008-06-26 |
Ind-Swift Laboratories Limited |
Process for the preparation of thiazolidine derivatives
|
EP2016076A2
(de)
*
|
2007-01-22 |
2009-01-21 |
Teva Pharmaceutical Industries Ltd. |
Polymorphe formen von rosiglitazon-hydrobromid und herstellungsverfahren dafür
|
TWI453041B
(zh)
*
|
2007-02-01 |
2014-09-21 |
Takeda Pharmaceutical |
固體型製劑
|
US8242151B2
(en)
|
2007-02-07 |
2012-08-14 |
Kyowa Hakko Kirin Co., Ltd. |
Tricyclic compounds
|
WO2008105326A1
(ja)
*
|
2007-02-28 |
2008-09-04 |
Ohara Chemical Industries, Ltd. |
2-イミノ-4-チアゾリジノン誘導体及び2,4-チアゾリジンジオン誘導体の製造方法
|
TW200901959A
(en)
|
2007-03-09 |
2009-01-16 |
Indigene Pharmaceuticals Inc |
Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
|
US8093236B2
(en)
*
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
DK2068909T3
(da)
|
2007-03-30 |
2012-08-06 |
Ambrx Inc |
Modificerede FGF-21-polypeptider og anvendelse heraf
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
US20160331729A9
(en)
|
2007-04-11 |
2016-11-17 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
WO2008128126A1
(en)
|
2007-04-11 |
2008-10-23 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
US11241420B2
(en)
|
2007-04-11 |
2022-02-08 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EA201401193A1
(ru)
|
2007-06-04 |
2015-08-31 |
Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити |
Триарильные соединения и композиции, их содержащие
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8168416B2
(en)
|
2007-07-26 |
2012-05-01 |
Amgen Inc. |
Modified lecithin-cholesterol acyltransferase enzymes
|
EP2190434B1
(de)
*
|
2007-08-17 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Purin-derivate zur verwendung in der behandlung von erkrankungen im zusammenhang mit fap
|
EP2203433B1
(de)
|
2007-09-14 |
2012-10-31 |
Metabolic Solutions Development Company LLC |
5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidin-2,4-dion zur Behandlung von Diabetes
|
US8304441B2
(en)
|
2007-09-14 |
2012-11-06 |
Metabolic Solutions Development Company, Llc |
Thiazolidinedione analogues for the treatment of metabolic diseases
|
WO2009035997A2
(en)
*
|
2007-09-14 |
2009-03-19 |
Cara Therapeutics, Inc. |
Benzo-fused heterocycles
|
US8722710B2
(en)
|
2007-09-26 |
2014-05-13 |
Deuterx, Llc |
Deuterium-enriched pioglitazone
|
US20090118514A1
(en)
*
|
2007-11-06 |
2009-05-07 |
Raghupathi Reddy Anumula |
Processes for preparing pioglitazone and its pharmaceutically acceptable salts
|
JP5334422B2
(ja)
*
|
2008-02-13 |
2013-11-06 |
株式会社トクヤマ |
5−{4−[2−(5−エチル−2−ピリジル)エトキシ]ベンジル}−2−イミノ−4−チアゾリジノンの製造方法
|
JP5197063B2
(ja)
*
|
2008-02-21 |
2013-05-15 |
株式会社トクヤマ |
2−ブロモ−3−{4−[2−(5−エチル−2−ピリジル)エトキシ]フェニル}プロピオン酸メチルの製造方法
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
WO2009133576A1
(en)
*
|
2008-04-28 |
2009-11-05 |
Erregierre S.P.A. |
A process for the preparation of 4-[2-(5-ethyl-2-pyridyl)ethoxy]nitrobenzene and pioglitazone
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
AU2009256157B2
(en)
|
2008-06-04 |
2014-12-18 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP2321341B1
(de)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
EP2327690A4
(de)
|
2008-08-06 |
2012-03-28 |
Kyowa Hakko Kirin Co Ltd |
Trizyklische verbindung
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
CN102177436B
(zh)
|
2008-08-12 |
2015-05-13 |
金帆德尔制药股份有限公司 |
鉴定疾病风险因子的方法
|
US8846315B2
(en)
|
2008-08-12 |
2014-09-30 |
Zinfandel Pharmaceuticals, Inc. |
Disease risk factors and methods of use
|
EP2326326B1
(de)
*
|
2008-08-15 |
2019-10-09 |
Boehringer Ingelheim International GmbH |
Dpp-4 inhibitoren zur verwendung in der wundheilung von diabetes-patienten
|
WO2010026882A1
(ja)
*
|
2008-09-02 |
2010-03-11 |
株式会社トクヤマ |
脱臭化水素化抑制剤
|
RU2011113823A
(ru)
|
2008-09-10 |
2012-10-20 |
БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) |
Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
|
KR20110068979A
(ko)
*
|
2008-10-10 |
2011-06-22 |
가부시끼가이샤 도꾸야마 |
카르보닐옥시 화합물의 제조 방법
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
JP5473303B2
(ja)
*
|
2008-12-01 |
2014-04-16 |
株式会社トクヤマ |
2−ブロモ−3−{4−[2−(5−エチル−2−ピリジル)エトキシ]フェニル}プロピオン酸メチルの製造方法
|
US20100144140A1
(en)
*
|
2008-12-10 |
2010-06-10 |
Novellus Systems, Inc. |
Methods for depositing tungsten films having low resistivity for gapfill applications
|
KR20110103968A
(ko)
|
2008-12-23 |
2011-09-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
유기 화합물의 염 형태
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
WO2010084638A1
(ja)
*
|
2009-01-20 |
2010-07-29 |
株式会社トクヤマ |
2-ブロモ-3-{4-[2-(5-エチル-2-ピリジル)エトキシ]フェニル}プロピオン酸メチルの脱臭化水素化を抑制する方法
|
JP2010208957A
(ja)
*
|
2009-03-06 |
2010-09-24 |
Tokuyama Corp |
結晶構造を有する5−{4−[2−(5−エチル−2−ピリジル)エトキシ]ベンジル}−2−イミノ−4−チアゾリジノン及びその製造方法
|
CN102348457A
(zh)
|
2009-03-11 |
2012-02-08 |
奥默罗斯公司 |
预防和治疗成瘾的组合物和方法
|
CA2766088C
(en)
|
2009-06-25 |
2017-06-13 |
Alkermes, Inc. |
Heterocyclic compounds for the treatment of neurological and psychological disorders
|
CA2766033C
(en)
|
2009-06-25 |
2016-09-20 |
Alkermes, Inc. |
Prodrugs of nh-acidic compounds
|
US20110065756A1
(en)
*
|
2009-09-17 |
2011-03-17 |
De Taeye Bart M |
Methods and compositions for treatment of obesity-related diseases
|
CN102655866B
(zh)
|
2009-11-13 |
2013-11-13 |
东丽株式会社 |
糖尿病的治疗或预防药
|
MX364651B
(es)
|
2009-11-27 |
2019-05-03 |
Boehringer Ingelheim Int Gmbh Star |
Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
|
US8912335B2
(en)
|
2009-12-15 |
2014-12-16 |
Metabolic Solutions Development Company, Llc |
PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
|
EP2526424A2
(de)
|
2010-01-22 |
2012-11-28 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, prävention und therapie von stoffwechselerkrankungen
|
EP2552442A1
(de)
|
2010-03-30 |
2013-02-06 |
Boehringer Ingelheim International GmbH |
Pharmazeutische zusammensetzung mit einem sglt2-hemmer und einem ppar-gamma-agonist sowie ihre verwendung
|
EP2566469B1
(de)
|
2010-05-05 |
2022-12-21 |
Boehringer Ingelheim International GmbH |
Kombinationstherapie
|
EP2585101A1
(de)
|
2010-06-24 |
2013-05-01 |
Boehringer Ingelheim International GmbH |
Diabetestherapie
|
JP2013538807A
(ja)
|
2010-09-01 |
2013-10-17 |
ルピン・リミテッド |
メトホルミンおよびピオグリタゾンを含む医薬組成物
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
MX355479B
(es)
|
2011-01-10 |
2018-04-19 |
Zinfandel Pharmaceuticals Inc |
Metodos y productos de farmaco para tratar enfermedad de alzheimer.
|
WO2012153312A1
(en)
|
2011-05-11 |
2012-11-15 |
Ranbaxy Laboratories Limited |
Process for the purification of pioglitazone
|
MX366629B
(es)
|
2011-07-15 |
2019-07-17 |
Boehringer Ingelheim Int |
Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
|
WO2013018899A1
(ja)
|
2011-08-03 |
2013-02-07 |
協和発酵キリン株式会社 |
ジベンゾオキセピン誘導体
|
WO2013068486A1
(en)
|
2011-11-08 |
2013-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of male infertility
|
EP2788384B1
(de)
|
2011-12-08 |
2017-08-09 |
Amgen Inc. |
Agonistische menschliche lcat-antigenbindende proteine und ihre verwendung in der therapie
|
ES2715562T3
(es)
|
2011-12-15 |
2019-06-04 |
Alkermes Pharma Ireland Ltd |
Profármacos de compuestos de amina secundaria
|
US9504679B2
(en)
|
2011-12-19 |
2016-11-29 |
Bjoern Colin Kahrs |
Pharmaceutical compositions comprising glitazones and Nrf2 activators
|
US20130158077A1
(en)
|
2011-12-19 |
2013-06-20 |
Ares Trading S.A. |
Pharmaceutical compositions
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP2638898A1
(de)
|
2012-03-16 |
2013-09-18 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Metformin- und Pioglitazonformulierung mit verschiedenen Freisetzungsprofilen
|
EP3685839A1
(de)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
ES2668310T3
(es)
|
2012-11-05 |
2018-05-17 |
Commissariat à l'énergie atomique et aux énergies alternatives |
Combinación de un agente anticanceroso tal como un inhibidor de la tirosina cinasa y un antagonista STAT5, preferiblemente una tiazolidindiona, para eliminar las células madre de cáncer hematológico in vivo y para prevenir la recidiva de cáncer hematológico
|
JP6800013B2
(ja)
|
2013-03-14 |
2020-12-16 |
ポクセル・ソシエテ・アノニムPoxel SA |
重水素化2,4−チアゾリジンジオン及び治療方法
|
US20140275138A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Cba Pharma, Inc. |
Method and products for treating diabetes
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
WO2014197720A2
(en)
|
2013-06-05 |
2014-12-11 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
US9815777B2
(en)
|
2013-09-22 |
2017-11-14 |
Jiva Pharma, Inc. |
Metformin salts to treat Type2 diabetes
|
JP2016534043A
(ja)
|
2013-10-09 |
2016-11-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
炎症促進性サイトカインのダウンレギュレーションに有用なグアニル酸シクラーゼのアゴニスト
|
CN106061940A
(zh)
|
2013-11-05 |
2016-10-26 |
本古里安大学内盖夫研究发展局 |
治疗糖尿病和由其引发的并发疾病的化合物
|
EP3666273A3
(de)
|
2014-01-15 |
2020-10-28 |
Poxel SA |
Verfahren zur behandlung von neurologischen, stoffwechsel- und anderen erkrankungen unter verwendung enantiomerenreinen deuterium-angereicherten pioglitazons
|
EP3110449B1
(de)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medizinische verwendung eines dpp-4-inhibitors
|
KR101606547B1
(ko)
*
|
2014-06-02 |
2016-03-28 |
김동연 |
공항 탑승객 위치조회시스템
|
US9434778B2
(en)
|
2014-10-24 |
2016-09-06 |
Bristol-Myers Squibb Company |
Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
|
US10034868B2
(en)
|
2014-11-04 |
2018-07-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
|
EP3025707A1
(de)
|
2014-11-27 |
2016-06-01 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Mehrschichtige tablette mit metformin und pioglitazon
|
UA123914C2
(uk)
|
2016-06-08 |
2021-06-23 |
Суппорт-Венче Гмбх |
Фармацевтичні комбінації для лікування раку
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
AU2017313296A1
(en)
|
2016-08-17 |
2019-02-14 |
Support-Venture Gmbh |
Method of preventing or treating hearing loss
|
TR201620309A2
(tr)
|
2016-12-30 |
2018-07-23 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
|
AU2018248578A1
(en)
|
2017-04-04 |
2019-10-17 |
Kinarus Ag |
Methods of preventing or treating ophthalmic diseases
|
WO2019154893A1
(en)
|
2018-02-08 |
2019-08-15 |
Strekin Ag |
Oral extended release pharmaceutical compositions for preventing or treating hearing loss
|
WO2019154895A1
(en)
|
2018-02-08 |
2019-08-15 |
Strekin Ag |
Gel formulation for preventing or treating hearing loss
|
US11273158B2
(en)
|
2018-03-05 |
2022-03-15 |
Alkermes Pharma Ireland Limited |
Aripiprazole dosing strategy
|
AU2019300135A1
(en)
|
2018-07-13 |
2021-01-28 |
Kinarus Ag |
Combinations of PPAR agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
|
CN111875598B
(zh)
*
|
2020-05-23 |
2023-10-10 |
白银京宇新药业有限公司 |
一种吡格亚胺的制备方法
|
US11767317B1
(en)
|
2020-06-30 |
2023-09-26 |
Poxel Sa |
Methods of synthesizing enantiopure deuterium-enriched pioglitazone
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
US20230263803A1
(en)
|
2020-08-11 |
2023-08-24 |
Kinarus Ag |
Methods of preventing or treating covid-19 and related viral diseases or disorders
|
CN116239601B
(zh)
|
2020-09-30 |
2023-10-13 |
映恩生物制药(苏州)有限公司 |
一种抗肿瘤化合物及其制备方法和应用
|
EP4385502A1
(de)
|
2022-12-15 |
2024-06-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Pharmazeutische formulierung mit metformin, pioglitazon und sglt-2-inhibitor
|
EP4385501A1
(de)
|
2022-12-15 |
2024-06-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Pharmazeutische formulierung mit linagliptin, pioglitazon und einem sglt-2-inhibitor
|